Mesoblast (ASX:MSB) DeferredTaxAndRevenue : A$0.00 Mil (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Mesoblast DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Mesoblast's current deferred tax and revenue for the quarter that ended in Jun. 2024 was A$0.00 Mil.

Mesoblast DeferredTaxAndRevenue Historical Data

The historical data trend for Mesoblast's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mesoblast DeferredTaxAndRevenue Chart

Mesoblast Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

DeferredTaxAndRevenue

Get a 7-Day Free Trial

Mesoblast Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
DeferredTaxAndRevenue	Get a 7-Day Free Trial															-	-	-	-	-

Mesoblast DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Mesoblast's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Mesoblast Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (ASX:MSB) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

MEOBF:USA MESO:USA LWB:Germany LWB:Germany

Address

55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000

Website

https://www.mesoblast.com

Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.